摘要
目的:观察不同剂量阿托伐他汀对冠心病稳定性心绞痛患者血清肿瘤坏死因子a(TNF-α)和低密度脂蛋白胆固醇(LDL-C)水平的影响。方法:用酶联免疫吸附法和生化发光分析法测定40例正常对照组和40例阿托伐他汀10mg组及39例阿托伐他汀20mg组冠心病患者治疗前后血清TNF-α和LDL-C水平的变化。结果:阿托伐他汀10mg及20mg组患者治疗12周后血清TNF-α和LDL-C水平明显降低,并且阿托伐他汀20mg组比阿托伐他汀10mg组血清TNF-α下降更明显,差异有显著性(P<0.05),但两组间LDL-C水平降低无显著性差异(P>0.05)。结论:阿托伐他汀可以降低冠心病患者血清LDL-C和TNF-α水平,减轻冠心病的炎症反应,并且这种机制独立于降脂作用以外。
Objective： To investigate the influence of the different dose Atorvastatin on the levels of Tumor necrosis factor-a（TNF-α） and Low-density lipoprotein cholesterol（LDL-C） in patients with Stable angina pectoris（SAP）.Methods： The levels of TNF-α and LDL-C were measured in 40 normal controls（NC group） and Atorvastatin 10mg group（n=40） and Atorvastatin 20mg group（n=39） before and after treatment in Stable angina pectoris（SAP）.Results： After treatment of 12 weeks,serum level of TNF-α and LDL-C in pa-tients with Stable angina pectoris was significantly lower,and the level of serum TNF-α in Atorvastatin 20mg group was significantly lower than those in Atorvastatin 10mg group（P〈0.05）,whereas there was no obvious difference about changes of the level of serum LDL-C between them（P〉0.05）.Conclusions： The concentration of TNF-α and LDL-C decreased after treatment of Atorvastatin in SAP,which indicated that Atorvastatin was available to anti-inflammation in addition to lipid-lowing effects.
出处
《现代生物医学进展》
CAS
2012年第2期333-336,共4页
Progress in Modern Biomedicine
